NCT00195221View on ClinicalTrials.gov

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

CompletedOBSERVATIONAL

Enrollment

166

Participants

Timeline

Start Date

February 28, 2005

Study Completion Date

November 30, 2007

Conditions

Hemophilia BAllergic Reactions

Trial Locations (38)

1090

Vienna

4420

Montegnée

19104

Philadelphia

20162

Milan

30322

Atlanta

35128

Padua

35340

Liffré

36100

Vicenza

38105

Memphis

43100

Parma

46009

Valencia

47004

Valladolid

48823

East Lansing

52242

Iowa City

55905

Rochester

61614

Peoria

67098

Strasbourg

75014

Paris

76104

Fort Worth

78207

San Antonio

83712

Boise

85016

Phoenix

88100

Catanzaro

90100

Palermo

92868

Orange

95124

Catania

95160

Montmorency

98105

Seattle

08903

New Brunswick

45404-1815

Dayton

Unknown

Brussels

T2N2T9

Calgary

HH20246

Hamburg

D-48413

Münster

5-80131

Naples

06100

Perugia

WV10 0QP

Wolverhampton

CF14 4XN

Cardiff

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00195221 - Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B | Biotech Hunter | Biotech Hunter